Interim safety analysis of a compassionate-use program (CUP) and early-access program (EAP) providing cabazitaxel (Cbz) plus prednisone (P) to patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel
Yazar
Heidenreich, Axel
Matus, Geoffrey
Hitier, Simon
Bahl, Amit
Basaran, Mert
Malik, Zafar I.
Di Lorenzo, Giuseppe
Ardavanis, Alexandros
Parente, Phillip
de Schultz, Wito
Saad, Fred
van Oort, Inge
Gerritsen, Winald R.
Aparicio, Luis M. Anton
Üst veri
Tüm öğe kaydını gösterKoleksiyonlar
- Bildiri [64839]